MindImmune Therapeutics

Targeting immune drivers of Alzheimer's disease

Kingston, United States · Founded 2016 · $12.4M raised

Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$12.4M
Last Round
$12.4M Series AJun 2022
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round for this company. The full record is or through the API.

About

MindImmune Therapeutics is a preclinical-stage biopharmaceutical company focused on developing novel immunotherapies for neurodegenerative diseases, with a primary focus on Alzheimer's Disease. Founded on the discovery that peripheral immune cells drive neurodegeneration, the company's lead program MITI-101 is a first-in-class monoclonal antibody that prevents neuroinflammation, neurite damage, and vascular pathology by blocking harmful immune cells from infiltrating the brain. Backed by investors including Dolby Family Ventures, Pfizer Ventures, and the Alzheimer's Drug Discovery Foundation, MindImmune completed a $30M Series A round in December 2025 to advance MITI-101 toward its first-in-human clinical trial in 2027.

Summary

MindImmune Therapeutics is a Biotech company based in Kingston, United States, founded in 2016. It has raised $12.4M in total across 1 round, most recently a $12.4M Series A round in Jun 2022.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJun 2022
$12.4M

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

MindImmune Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/mindimmune-therapeutics"><img src="https://indexed.vc/api/badge/company/mindimmune-therapeutics" alt="MindImmune Therapeutics on Indexed.vc" width="260" height="76" /></a>